[Retracted] Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation

Figure 8

Rocaglamide inhibits NF-AT via activation of the MAPKs, JNK, and p38. Jurkat T cells were treated with same condition described previously, and p38 kinase and JNK inhibitors (SB 203580 and SP 600125) were used, respectively, depending on the different group. Group A was normal treated, group B was treated with p38 kinase inhibitor (SB 203580), and group C was treated with JNK inhibitors (SP600125).

(a)

(b)

(c)